Perception of fecal microbiota transplantation in patients with ulcerative colitis in Korea: a KASID multicenter study Jebyung Park, Sung Noh Hong, Hong Sub Lee, Jongbeom Shin, Eun Hye Oh, Kwangwoo Nam, Gyeol Seong, Hyun Gun Kim, Jin-Oh Kim, Seong Ran Jeon The Korean Journal of Internal Medicine.2024; 39(5): 783. CrossRef
Immune checkpoint inhibitor therapies such as ipilimumab, are increasingly being used as a treatment option for a variety of cancers, including metastatic melanoma and have demonstrated effectively a prolonged survival. These agents have an immunological mode of action that predisposes patients to a number of immune-related adverse events, colitis being one of the most commonly encountered complications. The pathogenesis for the development of colitis is unclear, and there is a growing consensus that the ecosystem of the gastrointestinal microbiota plays a significant role. Based on this suspected connection, studies are being carried out to explore the changes in the microbiota in patients on these medications who develop colitis. Conceivably, the modulation of the gut microbiota could offer a therapeutic benefit. Fecal microbiota transplantation is one therapeutic option that is currently being investigated, though there are still more data needed to evaluate its efficacy. In this review, we recapitulate the mechanisms of action of immune checkpoint inhibitors, their adverse events, with a focus on colitis and the role gut microbiota are suspected to play, and finally discuss the microbiota modulation therapies being investigated.
Citations
Citations to this article as recorded by
What should intensivists know about immune checkpoint inhibitors and their side effects? Viktor Yordanov Zlatkov Aleksandrov, Fernando Martínez Sagasti, Juncal Pérez-Somarriba Moreno, Helena Huertas Mondéjar Medicina Intensiva (English Edition).2025; : 502135. CrossRef
Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy Despoina Chrysostomou, Lauren A. Roberts, Julian R. Marchesi, James M. Kinross Gastroenterology.2023; 164(2): 198. CrossRef
Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease Seung Yong Shin, Young Kim, Won-Seok Kim, Jung Min Moon, Kang-Moon Lee, Sung-Ae Jung, Hyesook Park, Eun Young Huh, Byung Chang Kim, Soo Chan Lee, Chang Hwan Choi Intestinal Research.2023; 21(1): 148. CrossRef
Obesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and Colitis Miho Kono, Malek Shatila, Guofan Xu, Yang Lu, Antony Mathew, Wasay Mohajir, Krishnavathana Varatharajalu, Wei Qiao, Anusha S. Thomas, Yinghong Wang Cancers.2023; 15(8): 2329. CrossRef
Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy Ankita Singh, Sharon Grace Alexander, Sunil Martin Frontiers in Immunology.2023;[Epub] CrossRef
Gut Microbiome and Colorectal Cancer Tae-Geun Gweon The Korean Journal of Gastroenterology.2023; 82(2): 56. CrossRef
Impact ofHelicobacter pyloriinfection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors Patrick T Magahis, Steven B Maron, Darren Cowzer, Stephanie King, Mark Schattner, Yelena Janjigian, David Faleck, Monika Laszkowska Journal for ImmunoTherapy of Cancer.2023; 11(10): e007699. CrossRef
Comments on Efficacy of a Synbiotic Containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in Elderly Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial Kwang Woo Kim Gut and Liver.2023; 17(6): 954. CrossRef
MTA1 aggravates experimental colitis in mice by promoting transcription factor HIF1A and up-regulating AQP4 expression Ping Li, Dong-Ping Shi, Tao Jin, Dong Tang, Wei Wang, Liu-Hua Wang Cell Death Discovery.2022;[Epub] CrossRef
Crosstalk between mucosal microbiota, host gene expression, and sociomedical factors in the progression of colorectal cancer Namjoo Kim, Jeong-An Gim, Beom Jae Lee, Byung il Choi, Hee Sook Yoon, Seung Han Kim, Moon Kyung Joo, Jong-Jae Park, Chungyeul Kim Scientific Reports.2022;[Epub] CrossRef
Exploration of Potential Gut Microbiota-Derived Biomarkers to Predict the Success of Fecal Microbiota Transplantation in Ulcerative Colitis: A Prospective Cohort in Korea Gi-Ung Kang, Sowon Park, Yeongyun Jung, Jai J. Jee, Min-Sueng Kim, Seungjun Lee, Dong-Woo Lee, Jae-Ho Shin, Hong Koh Gut and Liver.2022; 16(5): 775. CrossRef
Physical Activity as the Best Supportive Care in Cancer: The Clinician’s and the Researcher’s Perspectives Cécile Torregrosa, Frédéric Chorin, Eva Ester Molina Beltran, Cindy Neuzillet, Victoire Cardot-Ruffino Cancers.2022; 14(21): 5402. CrossRef
Inflammatory bowel disease (IBD) is a common diarrheal illness with gastrointestinal and extraintestinal manifestations and complications. The most common infectious complication associated with IBD is Clostridioides difficile infection (CDI). Active IBD predisposes to CDI due to alterations in the gut microbiome. C. difficile is a toxin producing bacterium leading to worsening of underlying IBD, increasing the risk of IBD treatment failure and an increased risk of hospitalization and surgery. Since the symptoms of CDI overlap with those of an IBD flare; it is prudent to recognize that the diagnosis of CDI is challenging and diagnostic tests (nucleic-acid and toxin-based assays) should be interpreted in context of symptoms and test performance. First line treatments for management of CDI in IBD include vancomycin or fidaxomicin. Recurrence prevention strategies should be implemented to mitigate recurrent CDI risk. One needs to monitor IBD disease progression and manage immunosuppression. The risk of recurrent CDI after a primary infection is higher in IBD compared to non-IBD patients. Microbiota restoration therapies are effective to prevent recurrent CDI in IBD patients. This review summarizes the epidemiology, pathophysiology, diagnostic testing, outcomes and management of both CDI and IBD, in CDI complicating IBD.
Citations
Citations to this article as recorded by
Special Issue “Bacterial Toxins and Cancer” Sara Travaglione, Francesca Carlini, Zaira Maroccia, Alessia Fabbri International Journal of Molecular Sciences.2024; 25(4): 2128. CrossRef
19-Year-Old Man With Abdominal Pain, Vomiting, Bloody Diarrhea, and Rash David L. Farrier, David Chiang, Amindra S. Arora Mayo Clinic Proceedings.2024; 99(6): 980. CrossRef
Pharmacological effects of ginseng and ginsenosides on intestinal inflammation and the immune system Linxian Zhao, Tongbo Zhang, Kai Zhang Frontiers in Immunology.2024;[Epub] CrossRef
Clostridioides difficile infection in inflammatory bowel disease: a clinical review Mengjun Tang, Chunhua Wang, Ying Xia, Jian Tang, Jiao Wang, Liang Shen Expert Review of Anti-infective Therapy.2024; 22(5): 297. CrossRef
Management of Clostridioides difficile infection: an Italian Delphi consensus Matteo Bassetti, Antonio Cascio, Francesco Giuseppe De Rosa, Marianna Meschiari, Roberto Parrella, Nicola Petrosillo, Alessandro Armuzzi, Flavio Caprioli, Francesco Dentali, Marcello Pani, Alberto Pilotto, Umberto Restelli, Maurizio Sanguinetti Journal of Antimicrobial Chemotherapy.2024; 79(9): 2103. CrossRef
Treatment outcomes of mild to moderate Clostridioides difficile infection in inflammatory bowel disease: an Australian experience Rachael Jacob, Virginia Chu, Watson Ng, Astrid‐Jane Williams, Susan Connor Internal Medicine Journal.2024; 54(12): 2009. CrossRef
Clinical outcomes for Clostridioides difficile associated diarrhea in inflammatory bowel disease patients versus non-IBD population: A retrospective cohort study Genady Drozdinsky, Alaa Atamna, Hagar Banai, Haim Ben-Zvi, Jihad Bishara, Noa Eliakim-Raz Medicine.2023; 102(6): e32812. CrossRef
Clostridioides difficile Toxin B Induced Senescence: A New Pathologic Player for Colorectal Cancer? Katia Fettucciari, Alessandro Fruganti, Fabrizio Stracci, Andrea Spaterna, Pierfrancesco Marconi, Gabrio Bassotti International Journal of Molecular Sciences.2023; 24(9): 8155. CrossRef
Low prevalence of Clostridioides difficile infection in acute severe ulcerative colitis: A retrospective cohort study from northern India Sandeep Mundhra, David Thomas, Saransh Jain, Pabitra Sahu, Sudheer Vuyyuru, Peeyush Kumar, Bhaskar Kante, Rajesh Panwar, Peush Sahni, Rama Chaudhry, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet Ahuja Indian Journal of Gastroenterology.2023; 42(3): 411. CrossRef
Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea Oh Chan Kwon, See Young Lee, Jaeyoung Chun, Kyungdo Han, Yuna Kim, Ryul Kim, Min-Chan Park, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park Frontiers in Medicine.2023;[Epub] CrossRef
Fidaxomicin treatment for Clostridioides difficile infection in patients with inflammatory bowel disease Andree H Koop, Paul M Travers, Sahil Khanna, Darrell S Pardi, Francis A Farraye, Jana G Hashash Journal of Gastroenterology and Hepatology.2023; 38(11): 1910. CrossRef
Clostridioides difficile Infection in Inflammatory Bowel Disease Patients: A Systematic Review of Risk Factors and Approach in Management Leslie Sangurima, Maujid Masood Malik, Nency Ganatra, Rosemary Siby, Sanjay Kumar, Sara Khan, Doju Cheriachan, Lubna Mohammed Cureus.2023;[Epub] CrossRef
Role of the Alteration in Calcium Homeostasis in Cell Death Induced by Clostridioides difficile Toxin A and Toxin B Katia Fettucciari, Fabrizio Dini, Pierfrancesco Marconi, Gabrio Bassotti Biology.2023; 12(8): 1117. CrossRef
Gut Microbiota Associated with Clostridioides difficile Carriage in Three Clinical Groups (Inflammatory Bowel Disease, C. difficile Infection and Healthcare Workers) in Hospital Field Elisa Martinez, Sebastien Crevecoeur, Carine Thirion, Jessica Grandjean, Papa Abdoulaye Fall, Marie-Pierre Hayette, Moutschen Michel, Bernard Taminiau, Edouard Louis, Georges Daube Microorganisms.2023; 11(10): 2527. CrossRef
Prevalence of Clostridium Difficile Infection (CDI) among Inflammatory Bowel Disease (IBD) Patients in Comparison to Non-IBD Patients in King Abdulaziz Medical City in Jeddah Ghassan Abdulrahman Sukkar, Syed Sameer Aga, Abdulrahman Hamid Alsamadani, Faisal Ghazi Almalki, Ali Saleh Alsudais, Abdulrahman Sulaiman Alquzi, Mohamed Eldigire Ahmed, Mushtaq Ahmad Mir, Moudi M. Alasmari, Shivendra Singh Interdisciplinary Perspectives on Infectious Diseases.2023; 2023: 1. CrossRef
Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching Analysis Eun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, Eun Young Kim, Yoo Jin Lee, Hyun Seok Lee, Joon Seop Lee, Sung Kook Kim, Yun Jin Jung, Sang-Bum Kang, Manasi Agrawal, Ryan Ungaro, Jean-Frederic Colombel Digestive Diseases and Sciences.2022; 67(7): 2866. CrossRef
Risk factors for Clostridioides difficile infection in children and adolescents with inflammatory bowel disease: a systematic review and meta-analysis Sheng-Bo Fang, Yan-Qing Song, Chun-Yan Zhang, Li-Bo Wang World Journal of Pediatrics.2022; 18(1): 27. CrossRef
Clostridium innocuum infection in hospitalised patients with inflammatory bowel disease Puo-Hsien Le, Cheng-Tang Chiu, Pai-Jui Yeh, Yu-Bin Pan, Cheng-Hsun Chiu Journal of Infection.2022; 84(3): 337. CrossRef
Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics Quan Lu, Mei-feng Yang, Yu-jie Liang, Jing Xu, Hao-ming Xu, Yu-qiang Nie, Li-sheng Wang, Jun Yao, De-feng Li Journal of Inflammation Research.2022; Volume 15: 1825. CrossRef
Clostridioides Infection in Patients with Inflammatory Bowel Disease Mi Rae Lee, Eun Soo Kim The Korean Journal of Gastroenterology.2022; 80(2): 66. CrossRef
Viral Hepatitis in Patients with Inflammatory Bowel Disease Seung Hwan Shin, Sang Hyoung Park The Korean Journal of Gastroenterology.2022; 80(2): 51. CrossRef
Exploration of Potential Gut Microbiota-Derived Biomarkers to Predict the Success of Fecal Microbiota Transplantation in Ulcerative Colitis: A Prospective Cohort in Korea Gi-Ung Kang, Sowon Park, Yeongyun Jung, Jai J. Jee, Min-Sueng Kim, Seungjun Lee, Dong-Woo Lee, Jae-Ho Shin, Hong Koh Gut and Liver.2022; 16(5): 775. CrossRef
Do We Have an Opportunity to Avoid Opportunistic Infections in Asian Patients with Inflammatory Bowel Disease? Suhyun Park, Sang Hyoung Park Gut and Liver.2022; 16(5): 663. CrossRef
Using next-generation sequencing to develop a Shigella species threshold and profile faecal samples from suspected diarrhoea cases Ann Smith Folia Microbiologica.2021; 66(3): 399. CrossRef
Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection Sarah Rotondo‐Trivette, Beibei Wang, Christopher Gayer, Riddhi Parsana, Yihui Luan, Fengzhu Sun, Sonia Michail Alimentary Pharmacology & Therapeutics.2021; 54(6): 792. CrossRef
Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease May be Favoured by the Effects of Proinflammatory Cytokines on the Enteroglial Network Gabrio Bassotti, Alessandro Fruganti, Giovanni Maconi, Pierfrancesco Marconi, Katia Fettucciari Journal of Inflammation Research.2021; Volume 14: 7443. CrossRef
Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infection Whitfield L. Knapple, David S. Yoho, Alexander Sheh, Joan Thul, Paul Feuerstadt Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef
Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies Muthukumaran Jayachandran, Shen Qu Reviews in Endocrine and Metabolic Disorders.2023; 24(6): 1189. CrossRef
Efficacy of Fecal Microbiota Transplantation for Recurrent C. Difficile Infection in Inflammatory Bowel Disease Raseen Tariq, Molly B Disbrow, John K Dibaise, Robert Orenstein, Srishti Saha, Dipesh Solanky, Edward V Loftus, Darrell S Pardi, Sahil Khanna Inflammatory Bowel Diseases.2020; 26(9): 1415. CrossRef
Faecal Microbiota Transplantation is Effective for the Initial Treatment of Clostridium difficile Infection: A Retrospective Clinical Review Niloufar Roshan, Annabel K. Clancy, Thomas J. Borody Infectious Diseases and Therapy.2020; 9(4): 935. CrossRef